GLOBUS MEDICAL (GMED) Stock: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$81.34
-0.32 (-0.39%)
▼
5d:
+6.04%
30d:
+9.52%
90d:
+3.95%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GMED shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GMED shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$124.87
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$77.54
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $81.34, which is considered extended relative to its 30-day fair value range of $73.99 to $76.69. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.2) compared to its historical average (17.4). Remarkably, the market is currently pricing in an annual earnings decline of 4.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $82.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $100.92 (+23.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMED is in a downtrend. The price is approaching resistance at $82.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMED scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $100.92 (+23.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$73.99 -
$76.69
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+6.1% above its trading range)
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.6% below Wall St target ($100.92)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$73.99 -
$76.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$74.61
Resistance Level
$82.01
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.15
Wall Street Target
$100.92
(+23.6%)
Revenue Growth (YoY)
5.9%
Earnings Growth (YoY)
-26.2%
Profit Margin
17.0%
Valuation Discount vs History
-4.5% cheaper
PE vs Historical
15.2 vs 17.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.5%
(market-implied from PE analysis)
1-Year Target
$77.99
(-5%)
2-Year Target
$74.48
(-9%)
3-Year Target
$71.12
(-13%)
3-Yr Target (if PE normalizes)
(PE: 15→17)
$81.69
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 7.8%)
$134.11
(+64%)
Base:
(SPY PE: 15.1, Growth: 7.8%)
$102.30
(+25%)
Bear:
(PE: 12.9, Growth: 7.8%)
$86.95
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 20.17 | Current EPS (TTM): $3.90
Bull Case
$119.62
(+47%)
Analyst growth 38.2%, PE expands to 22.2
Base Case
$108.75
(+33%)
Market implied 38.2%, PE stable at 20.2
Bear Case
$53.50
(-35%)
Severe decline -20.0%, PE contracts to 17.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.1 to 17.4
Stabilization Target:
$93.79
(+14.9%)
PE Expansion Potential:
+14.9%
Share & Embed Analysis
Last updated: October 23, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 52 HOLD |
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 41 HOLD |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 38 SELL |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 70 BUY |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
